INTRODUCTION

We present a case of recurrent COVID-19 pneumonia who underwent living-related renal transplantation 10 years ago. Returning of symptomatic immunocompromised patients who had a history of recovered COVID-19 disease with a positive real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) test after weeks to months of the previous episode is a challenging issue.

The novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified toward the end of 2019 in Wuhan, Hubei Province of China, as the cause of a new viral respiratory illness. Experience in the management of COVID-19 in the post-transplant population is limited. Due to its high infectivity, transplant patients are vulnerable, especially those with comorbidities. Post-transplant patients are often under immunosuppressive therapy; this immune deficiency state results in opportunistic infections. In the case of COVID-19 infection, these patients are particularly at risk of severe complications due to their immunosuppression and coexistence of comorbidities. Here, we present a case of renal transplant patient with recurrent COVID-19 pneumonia. Returning of symptomatic immunocompromised patients who had a history of recovered COVID-19 disease with a positive real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) test after weeks to months of the previous episode and also differentiation between reinfection and reactivation is a challenging issue.

CASE PRESENTATION

In August 2020, a 52-year-old man with a history of hypertension and ischemic heart disease and atrial fibrillation who underwent living-related renal transplantation 10 years ago was presented with fever, dry cough, dyspnea, and oxygen
saturation (SpO₂) of 89% on room air. Drug history was as follows: apixaban, atorvastatin, carvedilol, losartan, nitro-contin, and spironolactone. Maintenance immunosuppressive drugs consisted of prednisolone 5 mg/d, cyclosporine 50 mg every 12 hours, and mycophenolate mofetil 500 mg every 12 hours. Creatinine base was 1.7 mg/dl. Vital signs at admission were as follows: pulse rate: 96 beats/minute, respiratory rate: 22 breaths/minute, and blood pressure: 110/70 mmHg. rRT-PCR on samples obtained by oropharyngeal and nasopharyngeal swabs confirmed SARS-CoV-2 infection. Chest computed tomography scan was suggestive of COVID-19–induced pneumonia [Figure 1].

Supportive oxygen therapy with the nasal cannula at 3–4 liters per minute, and treatment with remdesivir 200 mg on day 1 and 100 mg once daily for five days were started. In addition, the mycophenolate mofetil was discontinued and cyclosporine 50 mg every 12 hours was continued. Also, the dose of prednisolone was increased to 15 mg/d. On day 4, the SpO₂ was 90% with relative improvement in dyspnea. On day 9, SpO₂ was 94% on room air. Supportive oxygen therapy was discontinued. On day 10, the patient was discharged. After discharge, cyclosporine 50 mg every 12 hours was continued. Also, prednisolone was continued at a dose of 15 mg/d and then reduced to 5 mg/d within three weeks. When the prednisolone dose reached 5 mg, mycophenolate mofetil 500 mg every 12 hours was started again.

47 days after discharge, the patient with seven-days history of progressive dry cough, fever, dyspnea, myalgia, vomiting, and weakness was presented to emergency department. His vital signs at admission were as follows: pulse rate 125 beats/minute, BP: 106/80, T: 38.6, and respiratory rate: 26 breaths/minute. SpO₂ was 86% on room air. rRT-PCR on samples obtained by oropharyngeal and nasopharyngeal swabs was positive for SARS-CoV-2 infection again. High-resolution chest CTs were obtained at admission [Figure 2]. and supplemental oxygen was administered through a nasal cannula at a rate of 5 liters per minute. Treatment with remdesivir 200 mg on day 1 and 100 mg once daily for five days and dexamethasone 8 mg/day was started. Mycophenolate mofetil was discontinued again, and cyclosporine 50 mg every 12 hours was continued. On day 3, the patient was afebrile and SpO₂ was 90% with improvement in dyspnea. On day 6, SpO₂ was 92% on room air. The patient’s condition improved over 12 days, and the patient was discharged with SpO₂ = 96%, afebrile, and improved cough with resolution of dyspnea. After discharge, cyclosporine 50 mg every 12 hours was continued. Also, prednisolone was continued at a dose of 15 mg/d and then reduced to 5 mg/d within three weeks. When the prednisolone dose reached 5 mg, mycophenolate mofetil 500 mg every 12 hours was started again. Table 1 shows laboratory data, and Table 2 shows immunosuppressive drugs and clinical characteristics of the patient in 2 episodes.

3 | DISCUSSION

We reported the clinical features and therapeutic course of a renal transplant recipient who experienced two episodes of COVID-19 pneumonia. Till now, cases of renal transplant patients with COVID-19 pneumonia are reported. Transplant recipients are at significant risk for COVID-19 infection. The immunocompromised state predisposes these patients to greater susceptibility to infection, more rapid progression to pneumonia, and more disease severity.5 Regarding the case discussed in this report, clinical and radiological characteristics of COVID-19 pneumonia were similar to those of other non-transplanted adult patients with COVID-19 pneumonia. However, the clinical manifestations in post-transplant patients may be atypical.6
Management of immunosuppression in transplant recipients with COVID-19 infection controversies due to the uncertain effects of immunosuppression on host viral defense and inflammatory response is reported. In general regarding treatment, there is a need to consider adjusting immunosuppressive agents while protecting graft function. In the cohort study by Chen et al. in 30 renal transplant patients, experience of withholding calcineurin inhibitors (CNIs) and antimetabolite during the management of COVID-19 pneumonia did not increase the risk of allograft rejection. In the study reported by Zhu et al., a total of 10 renal transplant recipients were evaluated and the use of CNIs in seven patients was completely halted for about 9 days, and the dosage was halved for one patient for 12 days, but none of the eight patients developed acute renal graft rejection. There is evidence that mycophenolate and SARS-CoV-2 may exert a synergic effect on depleting peripheral lymphocytes, which can be responsible for an aberrant immune reconstitution. It is suggested that in mycophenolate-containing immunosuppression regimen, mycophenolate was withdrawn with remaining other immunosuppressive drugs unchanged or with mild reduction. In the treatment of COVID-19 pneumonia, steroid use has emerged as a supportive treatment for COVID-19 pneumonia in guidelines, especially in severe cases. In a report by Fontana et al., a case of renal transplant with COVID-19 pneumonia was treated with tocilizumab and hydroxychloroquine. Maintenance immunosuppression consisted of cyclosporine plus steroid. At first in the management of treatment, cyclosporine dose was reduced by a half, and then, considering the lack of improvement in clinical conditions this drug was withdrawn. Also, oral steroid dose was increased. In the study by Karatas et al. in renal transplant patients, mycophenolate mofetil, mycophenolic acid, or azathioprine was stopped and CNIs were interrupted. High-dose methylprednisolone with or without initial pulse treatment was administered according to the severity of the disease. In the presented case, we discontinued mycophenolate, but cyclosporine and steroid were continued.

Another important entity is the recurrences of COVID-19 infection as viral reinfection or reactivation. Our case was hospitalized for two times with clinical and radiological features compatible with COVID-19 pneumonia. At first admission, the PCR test was positive. After 47 days, the patient was symptomatic again and the PCR test was positive.

### Table 1: Laboratory data in 2 episodes and at discharge

| Laboratory test | First episode | At discharge | Second episode | At discharge |
|-----------------|---------------|--------------|----------------|--------------|
| WBC (/µl)       | 4500          | 5100         | 6800           | 7200         |
| Lymphocyte (/µl)| 540           | 920          | 816            | 1150         |
| PLT (/µl)       | 398000        | 321000       | 343000         | 310000       |
| Hb (g/dl)       | 10            | 9.3          | 11.3           | 11           |
| BUN (mg/dl)     | 54            | 49           | 43             | 31           |
| Cr (mg/dl)      | 2.1           | 1.8          | 1.7            | 1.6          |
| AST (IU/L)      | 14            | 19           | 9              | 20           |
| ALT (IU/L)      | 20            | 31           | 12             | 10           |
| CRP (mg/l)      | 78            | 11           | 47             | 7            |

WBC: white blood cells; CRP: C-reactive protein; PLT: platelet; Hb: hemoglobin; BUN: blood urea nitrogen; Cr: creatinine; ALT: alanine aminotransferase; AST: aspartate aminotransferase.

### Table 2: Immunosuppressive drugs and clinical characteristics of patient in two episodes

| First episode | Second episode |
|---------------|----------------|
| Symptoms at onset | Dry cough, dyspnea, fever | Dry cough, fever, dyspnea, myalgia, vomiting, and weakness |
| Maintenance immunosuppression before admission | Prednisolone 5 mg/d | Prednisolone 5 mg/d |
| | Cyclosporine 50 mg every 12 hours | Cyclosporine 50 mg every 12 hours |
| | Mycophenolate mofetil 500 mg every 12 hours | Mycophenolate mofetil 500 mg every 12 hours |
| Immunosuppressive drugs after confirmation of COVID-19 pneumonia | Prednisolone 15 mg/day | Dexamethasone 8 mg/d |
| | Mycophenolate mofetil was discontinued | Mycophenolate mofetil was discontinued |
| | Cyclosporine 50 mg twice daily | Cyclosporine 50 mg twice daily |
| Antiviral therapy | Remdesivir | Remdesivir |
| SpO2 on room air | 89% | 86% |
| Duration of hospitalization | 10 days | 12 days |
viruses, so not all test positives will be a clinical recurrence. Also, there is evidence that shedding of viable virus in patients with profound immunosuppression after undergoing hematopoietic stem cell transplantation or receiving cellular therapies may last for at least 2 months. In patients that have respiratory symptoms after one episode and have positive PCR test, recurrences should be differentiated from COVID-19 complications such as pulmonary embolism or superinfection. Also, the persistence of traces of viral RNA that can be detected in respiratory samples up to 6 weeks after onset of symptoms in clinically cured patients should be considered. Pulmonary embolism and clues for superinfection and other differential diagnosis were ruled out in our case; hence in the presented case, episode of symptom recurrence after the first episode was attributed to COVID-19 infection, but we cannot differentiate between reinfection and reactivation due to lack of access to the viral genome sequencing test. We did not perform the PCR test at discharge. As stated in the studies, the PCR test is not necessary at the time of discharge. In addition, if the test reported negative, it may be attributed to false-negative causes and cannot be judged. The presented patient became symptomatic in two episodes 47 days apart with positive findings on CT scan and positive rRT-PCR test. In both episodes, we manage the disease course with corticosteroid and remdesivir. Cyclosporine was continued, and mycophenolate mofetil was stopped during our management; the patient was recovered eventually with resolution of signs and symptoms. Immunosuppressive factors could contribute to impair viral clearance and led to SARS-CoV-2 reactivation. In the study by Gousseff et al., it was hypothesized that in the case of healthy patients with mild symptoms at both episodes recurrence due to the prolonged exposition can be supposed, but in severe cases (eg, hypoxemic pneumonia), recurrence might have occurred due to a suboptimal control of the SARS-CoV-2 infection, allowing a second episode of viral replication.

4 | CONCLUSION

Transplant recipient patients are particularly at risk of greater severity of COVID-19 infection and complications due to their immunosuppression and coexistence of comorbidities. Recurrences of COVID-19 infection may occur in these patients, and differentiation between reinfection and reactivation is a challenging issue.

ACKNOWLEDGEMENTS

None. Published with written consent of the patient.

CONFLICT OF INTEREST

The authors declare that they have no competing interest.

AUTHOR CONTRIBUTIONS

S.A, F.Z, M.N, H.AT, and A.H acquired data, and analyzed and interpreted the data. A.H wrote the first draft of the manuscript. S.A revised the manuscript. All authors have read and approved the final manuscript.

ETHICAL APPROVAL

This research was approved by the ethics committee of Shahid Beheshti University of Medical Sciences (Ethical code: IR.SBMU.MSP.REC.1400.040). Written informed consent was obtained from the patient.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this case report type article as no new data were created or analyzed in this study.

ORCID

Atousa Hakamifard https://orcid.org/0000-0001-9456-2239

REFERENCES

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
2. Huang J, Lin H, Wu Y. COVID-19 in post-transplantation patients-report of two cases [published online ahead of print 2020]. Am J Transplant. 2020;10.
3. Cozzi E, Faccioli E, Marinello S, et al. COVID-19 pneumonia in lung transplant recipients: Report of 2 cases. Am J Transplant. 2020;20(10):2933-2937.
4. Abolghasemi S, Mardani M, Sali S, Honarvar N, Baziboroun M. COVID-19 and kidney transplant recipients. Transpl Infect Dis. 2020;22(6):e13413.
5. Fishman JA, Grossi PA. Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. Am J Transplant. 2020;20(7):1765-1767.
6. Michaels MG, La Hoz RM, Danziger-Isakov L, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020;20(7):1768-1772.
7. Zhu L, Xu X, Ma KE, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20(7):1859-1863.
8. Chen TY, Farghaly S, Cham S, et al. COVID-19 pneumonia in kidney transplant recipients: Focus on immunosuppression management. Transpl Infect Dis. 2020;22(5):e13378.
9. Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020;77(6):748-754.
10. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453-2462.
11. Colmenero J, Rodriguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74(1):148-155.
12. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. *Lancet (London, England)*. 2020;395(10225):683.

13. Fontana F, Alfano G, Mori G, et al. Covid-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. *Am J Transplant*. 2020;20(7):1902-1906.

14. Karatas M, Tatar E, Simsek C, et al. COVID-19 pneumonia in kidney transplant recipients: a promising treatment algorithm in the absence of a disease-specific drug. *J Med Virol*. 2021. https://doi.org/10.1002/jmv.27110

15. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chinese Med J*. 2020;133(9):1039.

16. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. *N Engl J Med*. 2020;383(26):2586-2588.

17. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. *Clin Infect Dis*. 2020;71(16):2249-2251.

18. Gousseff M, Penot P, Gallay L, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? *J Infect*. 2020;81(5):816-846.

How to cite this article: Abolghasemi S, Zolfaghari F, Naeimipoor M, Azhdari Tehrani H, Hakamifard A. COVID-19 reinfection or reactivation in a renal transplant patient. *Clin Case Rep*. 2021;9:e04672. https://doi.org/10.1002/ccr3.4672